Dr. Tong Chi Chung - Clinical Oncology
Highlights
- MCHK RegisteredVerified
- BilingualCantonese · English
- 1 LocationsKing's Park
- Specialist in Clinical OncologyBachelor of Medicine and Bachelor of Surgery (MBChB) · Fellow of the Royal College of Radiologists · Fellow of the Hong Kong College of Radiologists · Medical degree 1991
- InsuranceBeing compiled|See details
About
Dr. Tong Chi Chung practises Clinical Oncology in King's Park, Hong Kong. They speaks Cantonese, English.
Education
- Bachelor of Medicine and Bachelor of Surgery (MBChB)Bachelor of Medicine and Bachelor of Surgery (MBChB)1991
- Fellow of the Royal College of RadiologistsFellow of the Royal College of Radiologists1999
- Fellow of the Hong Kong Academy of Medicine (Radiology)Fellow of the Hong Kong Academy of Medicine (Radiology)2002
- FHKCRFellow, Hong Kong College of Radiologists2002
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Locations
Department of Clinical Oncology Queen Elizabeth Hospital 30 Gascoigne Road Kowloon
Get Directions →Fax: +852 2359 4782
King's Park
Insurance
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Tong Chi Chung? Claim page and update insurance →
FAQ
Research and publications
20 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes.Cancers · 2022
- International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.The Lancet. Oncology · 2022
- Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.Oral oncology · 2022
- Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.Cancers · 2022
- Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.BMC infectious diseases · 2021
- Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy.Frontiers in oncology · 2020
- The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.International journal of cancer · 2019
- Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.British journal of cancer · 2019
- Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2019
- DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?The Lancet. Oncology · 2019
- Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.Liver cancer · 2018
- A Novel <i>DPYD</i> Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive <i>DPYD</i> Genotype Screening.Frontiers in oncology · 2018
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer